5 Top Gainers In Healthcare Sector (HARP, NXTC, TPTX…)

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. Harpoon Therapeutics Inc. (HARP)

Harpoon Therapeutics is a clinical-stage immuno-oncology company.

Gained 19.91% to close Wednesday's (Aug.21) trading at $13.67.

News: No news

Recent event:

The Company went public on the Nasdaq Global Select Market on February 8, 2019, offering its shares at a price of $14 each.

Clinical Trials & Near-term Catalysts:

-- The Company's lead product candidate is HPN424, currently in phase I clinical trial for metastatic castration-resistant prostate cancer. Interim results from this study are expected to be presented at a medical meeting in the first half of 2020. -- A phase I/IIa trial of HPN536, a mesothelin-targeting T cell engager, for ovarian and other mesothelin-expressing solid tumors, is ongoing, with proof of concept data expected to be presented in 2020. -- An IND for HPN217 is expected to be filed by the end of 2019, and a phase I trial is planned for initiation in the first quarter of 2020. HPN217 is a potential treatment for multiple myeloma. -- A phase I trial of HPN328 for the treatment of small-cell lung cancer is expected to be initiated in 2020.

2. Assertio Therapeutics (ASRT)

Assertio Therapeutics, formerly known as Depomed Inc., currently markets three FDA-approved products, and its core areas of focus include neurology, orphan, and specialty medicines.

Gained 15.04% to close Wednesday's trading at $1.53.

News: No news

Recent event:

On August 7, 2019, the Company reported financial results for the second quarter ended June 30, 2019. The total net product sales in the recent second quarter declined to $25.94 million from $26.84 million in the year-ago quarter.

Upcoming event:

On September 10, 2019, the Company will make a presentation at the 17th Annual Morgan Stanley Global Healthcare Conference.

3. Mustang Bio Inc. (MBIO)

Mustang Bio is a clinical-stage biopharmaceutical company focused on developing cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases.

Gained 14.81% to close Tuesday's trading at $4.65.

News: No news

Clinical Trials and Near-term Catalyst:

-- In April of this year, promising data from a phase I/II clinical trial of MB-107 for severe combined immunodeficiency, also referred to as "bubble boy disease" was published in the New England Journal of Medicine. -- A phase I trial of CAR T therapy MB-103 in HER2-positive breast cancer with brain metastases is underway. -- The Company expects to initiate a multi-center Phase 1/2 clinical trial of MB-102 in acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm (BPDCN) and high-risk myelodysplastic syndromes in the second half of 2019.

4. NextCure Inc. (NXTC)

NextCure Inc is a clinical-stage biopharmaceutical company developing next-generation immunomedicines for cancer and other immune-related diseases by restoring normal immune function.

Gained 13.89% to close Wednesday's trading at $29.52.

News: No news

Recent event:

The Company made its debut on The Nasdaq Global Select Market on May 9, 2019, offering its shares at a price of $15 each.

Near-term Catalyst:

-- A Phase 1/2 clinical trial to evaluate NC318 as a monotherapy in patients with advanced or metastatic solid tumors is enrolling patients. The Phase 1 portion of the trial is designed to assess the safety and tolerability of NC318 and remains on track for completion in the fourth quarter of 2019. -- An investigational new drug application for the second cancer drug candidate, NC410, to advance the compound in phase I testing is expected to be submitted to the FDA in the first quarter of 2020.

5. Turning Point Therapeutics Inc. (TPTX)

Turning Point Therapeutics is a clinical-stage biopharmaceutical company developing targeted oncology therapies.

Gained 13.85% to close Wednesday's trading at $52.28.

News: No news

Pipeline & Near-term Catalysts:

-- The Company's lead drug candidate is Repotrectinib, under a phase I/II trial for the treatment of patients with ROS1+ advanced NSCLC and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors, dubbed TRIDENT-1. The phase I portion of the trial has yielded promising results, according to the Company. -- The phase II portion of the TRIDENT-1 study was initiated in June of this year. Early interim results from initial patients enrolled in the study are expected during the second half of 2020.

Also in the pipeline are TPX-0046, TPX-0022 and a series of next-generation ALK inhibitors.

-- A phase I clinical study of TPX-0022 in patients with advanced solid tumors harboring genetic alterations in MET was initiated in July of this year. Initial data from this study are expected during the second half of 2020. -- TPX-0046 is expected to enter phase I trial in the second half of this year, pending IND submission and clearance.